388 results
Page 4 of 20
8-K
EX-99.1
1yk6gk wx
13 Oct 20
Other Events
8:11am
8-K
EX-10.1
d9sv yqs617t0e
25 Sep 20
Entry into a Material Definitive Agreement
4:38pm
424B5
q7tq0 4py
25 Sep 20
Prospectus supplement for primary offering
4:23pm
8-K
EX-99.1
whpjkg49w0uw xvoq9
31 Jul 20
ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results
8:41am
8-K
EX-99.1
1m3wzwj56 kc
22 Jul 20
ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer
4:10pm
8-K
EX-99.1
2fyfwj2jl76azqqa9
1 May 20
ImmunoGen Reports Recent Progress and First Quarter 2020 Financial Results
6:35am
8-K
EX-99.1
exyxk3n21 dyt
14 Feb 20
ImmunoGen Reports Recent Progress and 2019 Financial Results
6:36am
8-K
EX-99.1
sppp40 86
27 Jan 20
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:13pm
8-K
EX-99.2
ecp1ssrfwoibh3c66i
23 Jan 20
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-1.1
vz1lyaxx
23 Jan 20
Entry into a Material Definitive Agreement
4:07pm
424B5
goywl1beszj7a3
23 Jan 20
Prospectus supplement for primary offering
4:05pm
8-K
xujk2
22 Jan 20
ImmunoGen Announces Proposed Public Offering of Common Stock
4:09pm
8-K
EX-99.1
452osv
22 Jan 20
ImmunoGen Announces Proposed Public Offering of Common Stock
4:09pm
424B5
z2f ouhj76552
22 Jan 20
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
h26pqxky
13 Jan 20
Results of Operations and Financial Condition
6:07am
8-K
EX-99.1
30stfevq9
17 Dec 19
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
xs7lrj y2
17 Dec 19
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
6:37am